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Abstract 
Rheumatoid arthritis (RA) is a widespread, debilitating autoimmune disease characterized by 
painful inflammation of the joints. Current treatments for RA are either ineffective, expensive, or 
have undesirable effects, such as an adverse immune response. To mitigate these effects, we 
have designed an exosome-based treatment for inflammation. We chose to utilize exosomes for 
their longer half-life in the body, better penetrative capacity, and biocompatibility, thus 
improving upon previous RA treatments. To do this, we created a stable cell line to produce 
exosomes modified at the surface to express a tumor necrosis factor receptor (TNFR), which 
possesses the ability to act as a decoy and soak up soluble tumor necrosis factor alpha (TNFα), a 
notable cytokine responsible for inducing inflammation. Exosomes were then harvested from this 
cell line and characterized with various imaging techniques to confirm that our desired 
modifications had been made. Then we tested the efficacy of our experiment in two models: 
direct treatment and coculture. Both models showed decreased levels of inflammation with the 
addition of our modified, treatment exosomes. If proven to be clinically successful, this therapy 
has the potential to be the first ever exosome decoy treatment.  
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1. Introduction 
 
1.1 Background and Motivation 
Over 1.3 million people suffer from rheumatoid arthritis (RA) in the United States. RA is a 
chronic autoimmune disease of unknown origin, the hallmark symptom of which is swollen, 
painful joints.1 Eventually, this condition can result in the irreversible destruction of joints. 
Unfortunately, current treatments for RA are limited and have numerous drawbacks. The most 
effective treatments for RA are protein-based biologics that prevent inflammation-causing 
cytokines from binding to cells, however, use of these drugs can result in suppression of the 
immune system, leading to serious and sometimes fatal infections. For this reason, we aimed to 
develop and test an anti-inflammatory therapy for RA that utilizes biocompatible nanoparticles 
called exosomes. 
 
1.2 Literature Review 
1.2.1 Rheumatoid Arthritis 
As a progressive autoimmune disease, RA results in chronic joint pain and stiffness that 
drastically reduces the quality of life in the people it affects. Typically, the disease manifests 
itself through severe discomfort in the hands and wrists, though it may also affect other regions 
of the body.2 The underlying pathophysiology behind RA is the body’s immune system attacking 
the joints, which leads to thickening of the synovium embedded in the joint capsule. In the 
disease mechanism, macrophages of the immune system secrete inflammatory cytokines: 
Interleukin-1 (IL-1), Interleukin-6 (IL-6) , and Tumor Necrosis Factor α (TNFα).3 Together, 
these cytokines stimulate fibroblast-like synoviocytes to proliferate uncontrollably, in part by the 
phenotypic suppression of contact inhibition. These fibroblast-like synoviocytes attract other 
                                                
1 S. Cohen and P. Emery, “The American College of Rheumatology/European League Against Rheumatism Criteria 
for the Classification of Rheumatoid Arthritis: A Game Changer,” Arthritis & Rheumatism 62 no. 9 (2010): 2592-
2594, doi:10.1002/art.27583. 
2 “NIAMS Health Information on Rheumatoid Arthritis,” National Institute of Arthritis and Musculoskeletal and 
Skin Disease, March, 21, 2018, Accessed June 10, 2018, https://www.niams.nih.gov/health-topics/rheumatoid-
arthritis. 
3 Ankur Shah,  Harrison's Principle of Internal Medicine, 18th ed., United States: McGraw Hill, 2738. 
 2 
immune cells to the area, creating a chain of deleterious positive feedback that results in 
osteoclast and protease activation.4 This contributes to the degradation of both protective 
cartilage and bone, as observed in RA pathology.  
 
1.2.2 TNFα and the Inflammation Pathway 
As indicated above, pro-inflammatory cytokines IL-1, IL-6, and TNFα represent major players in 
the RA transduction cascade. Of these cytokines, TNFα responds the most rapidly, only a few 
hours after stimulation, and is found in high concentrations in the synovial fluid of affected 
patients.5 Further, research conducted on the interplay between these cytokines has illuminated 
the desirability of selective TNFα inhibition, which is sufficient in mitigating the downstream 
effects of IL-1 and IL-6, and thus reducing the inflammation response in RA.6 At the cellular 
level, inflammation is mediated through the NFkB pathway. When TNFα binds to the TNF 
receptor on the exterior cell membrane, the receptor stimulates an enzyme that activates NFkB, a 
transcription factor consisting of p65 and p50. Translocation of NFkB to the nucleus allows it to 
bind upstream of quintessential inflammation response elements, promoting transcription and 
upregulation of inflammation inducing cascades.7 Section 1.2.4 explains how we took advantage 
of this pathway to quantify inflammation in a cell culture model. 
 
1.2.3 Exosomes and their Therapeutic Potential 
Exosomes are naturally secreted nanovesicles roughly 30-100 nm in size originating from the 
intraluminal budding of multivesicular endosomes (MVEs).8 Once thought to be a system of 
cellular waste elimination, exosomes have recently been characterized as a model for cell-cell 
communication, revitalizing interest in their drug delivery capacity.9 Unlike liposomes and other 
synthetic nanoparticle vehicles, exosomes contain transmembrane and membrane-bound proteins 
                                                
4 Shah, 2738.  
5 M. Feldmann et al, “Definition of TNFα as a Therapeutic Target for Rheumatoid Arthritis,” TNF-Inhibition in the 
Treatment of Rheumatoid Arthritis, 2004, 1-22, doi: 10.3109/9780203624388. 
6 Feldmann.  
7 Z. Zhang et al, “AAV-Based Dual-Reporter Circuit for Monitoring Cell Signaling in Living Human Cells,” 
Journal of Biological Engineering 11, no. 1 (2017), doi:10.1186/s13036-017-0060-9, 18.   
8 J. Kowal and M. Tkach, “Biogenesis and Secretion of Exosomes,” Current Opinion in Cell Biology 29 (2014): 
116-125, Doi: 10.1016/j.ceb.2014.05.004. 
9 M. Rashed et al, “Exosomes: From Garbage Bins to Promising Therapeutic Targets,” International Journal of 
Molecular Science 18, no. 3 (2017): 538, Doi: 10.3390ijms18030538. 
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that could promote the endocytosis and delivery of their internal content.10 So far, exosomes 
have been suggested in a wide range of animal disease models, from cancer,11 to parasitic 
infection,12 and even as far as traumatic brain injury.13 
 
1.2.3.1 Exosome Biogenesis  
Exosome biogenesis is intimately associated with the endosomal system. Molecules on the 
plasma membrane are delivered to early endosomes in endocytic vesicles. Early endosomes 
mature into late endosomes where invagination of the membrane causes the formation of 
multivesicular bodies (MVBs) containing intraluminal vesicles.14 Finally, fusion of MVBs with 
the plasma membrane causes the release of the intraluminal vesicles, now called exosomes.  
 
Another known fate of late endosomes is fusion with the lysosome organelle, a transfer 
considered to be unidirectional.15 Soluble molecules within late endosomes, including 
intraluminal proteins tagged with ubiquitin, are transported to the lysosome for degradation.16 
Hence, molecules potentially secreted in exosomes could otherwise find themselves degraded. 
This alternate fate is important to note in our project to observe the extent of colocalization of 
our therapeutic exosomes within the lysosomal compartment. Unfortunately, not much is 
understood about cellular selection between the fates of late endosomes or MVBs since the 
population is thought to be distinctly heterogenous.17 
 
 
 
                                                
10 S. Kamerkar, and V. LeBleu, “Exosomes Facilitate Therapeutic Targeting of Oncogenic KRAS in Pancreatic 
Cancer,” Nature, 2017, 546: 498-503, Doi: 10.1038/nature22341. 
11 D. Moris and E. Beal, “Role of Exosomes in Treatment of Hepatocellular Carcinoma,” Surgical Oncology 26, no. 
3 (2017): 219-228, doi: 10.1016/j.suronc.2017.04.005. 
12 F. Aline et al, “Toxoplasma Gondii Antigen-Pulsed-Dendritic Cell-Derived Exosomes Induce a Protective 
Immune Response Against T. Gondii Infection,” Infection and Immunity 72, no. 7 (2004): 4127-37, doi: 
10.1128/IAI.72.7.4127-4137. 
13 Y. Xiong et al, “Emerging Potential of Exosomes for Treatment of Traumatic Brain Injury,” Neural Regeneration 
Research 12, no. 1: 19-22, doi: 10.4103/1673-5374.198966. 
14 N. Hessvik and A. Llorente, “Current Knowledge on Exosome Biogenesis and Release,” Cellular and Molecular 
Life Sciences 75, no. 2: 193-208, doi:10.1007/s00018-017-2595-9. 
15 Hessvik. 
16 Hessvik. 
17 Hessvik.  
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1.2.3.2 Tetraspanin CD63 
CD63 is the most abundant of tetraspanin proteins and it is considered a hallmark localizer of 
exosomes.18 Tetraspanins consist of both intra and extra-vesicular domains, making them a great 
target for modifications.19 Previous studies have shown that both RFP and GFP have been fused 
with tetraspanin CD63 and used to track the secretion and uptake of modified exosomes.20 
 
1.2.4 Inflammation Reporter 
In order to quantify inflammation in vitro, we utilized a reporter that signaled when the NF-kB 
pathway was initiated. Specifically, we used a HEK 293 NF-κB GFP/Luciferase reporter. The 
reporter uses a adeno-associated virus (AAV) helper system that contains transcription factor 
response elements (TREs) followed by a minimal CMV promoter and GFP-2A-Firefly-
luciferase.21 When this dual reporter cell line is in the presence of the inflammatory cytokine 
TNFα, Nf-KB is activated and binds to the TREs which leads to the expression of both GFP and 
luciferase, which can be quantified and related to cellular levels of inflammation.22  
 
 
 
 
 
 
 
 
 
 
 
                                                
18 Z. Stickney et al, “Development of Exosome Surface Display Technology in Living Human Cells,” Biochemical 
and Biophysical Research Communications 472, no. 1 (2016): 53-59, doi: 10.1016/j.bbrc.2016.02.058, 53. 
19 Stickney, 53.  
20 Stickney, 54. 
21 Zhang, 2.   
22 Zhang, 5. 
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1.3 Drawbacks of Current Technologies 
Given rheumatoid arthritis prevalence in the US population, there is a plethora of medications 
and therapies currently used for treatment. However, many have significant drawbacks impacting 
patient quality of life. In Table 1-1, we outline the mechanism of current treatments, list their 
drawbacks, and propose how an exosome-based therapy may circumvent these problems.  
 
Table 1-1: Drawbacks of Current RA Treatments 
Treatment Mechanism of action Treatment side effects Exosome-based therapy 
solutions 
Non-steroid anti-
inflammatory drugs 
(NSAIDs) 
Reduces vasodilation by 
inhibiting production of 
prostaglandins23 
Adverse reactions in those 
with hepatic and renal 
sensitivities24 
Exosomes will not block 
prostaglandins 
Steroids Mimics anti-inflammatory 
properties of naturally 
secreted hormones10 
Can displace natural 
steroid production, 
creating dependency10 
Localized exosome 
therapy will not displace 
natural exosomes 
Disease modifying 
antirheumatic drugs 
(DMARDs) 
Reduces proinflammatory 
cytokines by reducing 
folate levels25 
Long-term liver toxicity12 Exosomes will not act on 
folate levels 
Biologics Inhibits inflammatory 
cytokines TNFɑ and IL-
626 
Increased infection risk, 
drug becomes ineffective 
if doses are skipped27 
Antibodies will not 
develop against treatment 
exosomes 
Physical therapy Maintains muscle strength 
and reduces 
inflammation28 
Accessibility and cost Not applicable 
Joint replacement 
surgery 
Removes joints too eroded 
to function29 
Risks of surgery, long 
recovery time 
Not applicable 
                                                
23 E. Ricciotti and G. Fitzgerald, “Prostaglandins and Inflammation,” Arteriosclerosis, Thrombosis, and Vascular 
Biology 31, no. 5 (2011): 986–1000, doi: 10.1161/atvbaha.110.207449. 
24 L. Crofford, “Use of NSAIDs in Treating Patients with Arthritis,” Arthritis Research & Therapy 15 (2013).  
25 M. Nurmohamed and B. Dijkmans, “Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying 
Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis,” Drugs 65, no. 5 (2005): 661-694, doi: 
10.2165/00003495-200565050-0006.  
26 J. Singh et al, “Adverse Effects of Biologics: A Network Meta-Analysis and Cochrane Overview,” Cochrane 
Database of Systematic Reviews 2. 
27 L. Putte et al, “Adalimumab,” TNF-Inhibition in the Treatment of Rheumatoid Arthritis, 2004, 71-88, doi: 
10.3109/9780203624388-5. 
28 V. Kavuncu and D. Evcik, “Physiotherapy in Rheumatoid Arthritis,” Medscape General Medicine 6, no. 2, doi: 
10.3109/9780203624388-5.  
29 “Joint Replacement Surgery,” National Institute of Arthritis and Musculoskeletal and Skin Diseases, October 4, 
2017, Accessed June 11, 2018. https://www.niams.nih.gov/health-topics/joint-replacement-surgery.   
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1.4 Project Goals and Constraints 
Our project goal is to take the specificity of biologics one step further using naturally secreted 
nanoparticles. However, it is important to note that our project is only one step in a long line of 
research necessary to safely implement a novel RA therapeutic. For instance, we cannot measure 
general clinical outcomes such as liver toxicity due to institutional limitations on animal testing, 
nor do we have the means to perform purity analysis. Our project, furthermore, is far from all-
encompassing; we do not aim to replace physical therapy or joint replacement surgery with our 
exosomal therapy, as they are required in extreme circumstances. Instead, we evaluated the 
efficacy of our exosomes in a cell culture model, extrapolating existing literature on exosomal 
treatment to make clinical predictions when appropriate. For this reason, we propose a proof of 
concept for reducing inflammation in vitro. 
 
Our project is nominally divided into three phases or goals. The first goal of our project was to 
create a stable cell line that produced engineered exosomes. The second goal involved 
confirmation of the desired modifications via fluorescence imaging. Following successful 
production of our therapeutic exosomes, we tested their efficacy in a quantitative assay in the 
third and final goal. 
 
1.4.2 Phase 1: Production 
In phase 1, we focused on creating a stable cell line that produced engineered exosomes capable 
of preventing inflammation. Next, we harvested these exosomes and store them for phases 2 and 
3 of our project.  
 
1.4.3 Phase 2: Characterization 
In phase 2, we aimed to confirm that we had made the desired modifications to our stable cell 
lines. We followed the biogenesis of exosomes using various markers to ensure that our TNFR 
had been added to the surface of the exosomes.  
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1.4.4 Phase 3: Testing 
In phase 3, we utilized our reporter cell line to determine the effect of our engineered exosomes 
on the inflammatory response of human cells in vitro.  
 
1.5 Back-Up Plan 
Despite careful aseptic technique, research with mammalian cell lines is notably susceptible to 
unforeseen contamination in the form of bacteria or fungi. In order to prevent contamination that 
could jeopardize the timeline of our project, we continually made frozen copies of our stable cell 
lines to store at -80C. Although this procedure was critically important to staying ahead of 
deadlines, it is hardly unique to our project.  Project specific back-up plans include the option to 
engineer TNFR onto a different scaffold, such as VSVG or RD114, if our CD63-TNFR-GFP 
exosomes are not successful in significantly reducing inflammation.  Secondly, we could refocus 
our attention on other inflammatory cytokines implicated in the RA transduction cascade like IL-
1 and IL-6. 
 
1.6 Significance 
If our proposed therapy is successful in preventing inflammation in-vitro, it could be one of the 
first exosome-based therapies to be tested in animals and clinical trials. Due to the natural 
stability of exosomes in the body and the fact that they do not initiate an adverse immune 
response, our proposed therapy has the potential to be as effective as DMARDs or biologics 
without the significant drawbacks of those classes of drugs. The technology utilized by our 
proposed exosome therapy could also be applied to a number of other therapeutic uses, such as 
gene therapies, immunotherapies, and targeted drug delivery.  
 
1.7 Team Management 
As a team, we have shared equal responsibility maintaining our cell lines, designing and 
performing experiments, and analyzing data. Dr. Lu provides guidance through regular 
correspondence and weekly meetings.  
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1.8 Budget 
See Table 1-2 below for our project budget. 
Table 1-2: Project Budget 
Flasks and Plates $250 
Fetal Bovine Serum $250 
Culture Media $500 
TNFα $210 
Serum Free Media $120 
Luciferase Assay $250 
Endosomal Stains $500 
Transfection Reagent $1000 
Total Cost $3080 
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1.9 Timeline 
Our project timeline is outlined below in Table 1-3. 
Table 1-3: Project Timeline 
 Fall Quarter Winter Quarter Spring Quarter 
Establish Cell Lines      X   
Maintain Cell Lines X X X 
Characterize and Image 
Exosomes 
X X  
Track exosomes through 
endosome pathway 
 X  
Evaluate Dose Response  X X 
Write Thesis  X X 
Present Results   X 
 
  
 10 
2. Creating Stable Cell Lines to Produce Therapeutic 
Exosomes 
 
2.1 Design Description 
In order to produce and collect modified exosomes efficiently, we decided to create two stable 
cell lines. Our treatment stable cell line utilizes CD63 tetraspanin to anchor a TNFR along with 
GFP to the surface of exosomes. Based on prior experimentation, we anticipated that this TNFR 
on the surface of the exosomes would soak up excess TNFα and thereby prevent the initiation of 
inflammation in cells. We also created a control stable cell line for experimentation purposes, 
replacing the TNFR with RFP. Both cell lines utilized HEK 293 cells transfected with our 
desired DNA constructs and a puromycin resistance gene in order to select for our transfected 
cells. 
 
2.2 Key Constraints 
To prevent cells without our desired construct from growing, we grew our stable cell lines in 
media containing the antibiotic puromycin for a period of 10 weeks. Antibiotics can be harsh on 
cells, so finding the correct dose that would kill cells without our desired modifications but 
would also allow the resistant cells to thrive can be difficult. One must consistently monitor the 
cells to ensure that only the cells without the desired modifications (the cells that do no fluoresce 
green) are killed off.  
 
2.3 Expected Results 
We expected to see GFP expressed in all of our HEK 293 CD63-TNFR-GFP cells and both GFP 
and RFP expressed in all of our HEK 293 CD63-RFP-GFP cells after the 10 week treatment with 
puromycin. This period of treatment should have been sufficient for killing off any untransfected 
cells. Final results are shown in section 6.1. 
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2.4 Materials and Methods 
The following table (Table 2-1) contains the necessary materials to create our stable cell lines.  
Table 2-1: Materials for Creating Stable Cell Lines 
Material Company/Brand Model # 
Passaging Mammalian Cells 
Materials (See Appendix) 
  
HEK 293 cells  N/A 
HEK 293 CD63-RFP-GFP Stable 
Cell Line 
  
DMEM + 10% FBS + PS media   
Puromycin 
ThermoFisher Scientific A1113802 
FuGene HD Transfection Reagent Promega E231A 
Microcentrifuge tubes Sigma-Aldrich/ Eppendorf Safe-
Lock  
T9661 
Opti-MEM Reduced Serum Media 
ThermoFisher Scientific 31985062 
DNA Plasmids (CD63-TNFR-GFP 
and CD63-RFP-GFP) 
Genscript  
 
Methods  
Day 1 
1.  Use protocol for passaging mammalian cells onto a 60mm x 15mm dish and incubate at 37°C 
for 24 hours. 
Day 2 
2. After 24 hours, combine reduced-serum media (Opti-MEM) and FuGene HD Transfection 
Reagent at a ratio of 2µg of DNA per 4µl of transfection reagent. 
3. Incubate at room temperature for 5 minutes.       
 12 
4. Carefully add 1.5µg/mL of DNA plasmid into the reduced-serum media (Opti-MEM) and 
transfection reagent mixture.   
5. Incubate the mixture at room temperature for 20-30 minutes. 
6. Carefully add the mixture to the cell culture dish. 
7. Incubate the dish at  37°C for 24 hours. 
Days 4-70 
8. Add 5µg/ml of puromycin to 50 mL of DMEM + 10% FBS + PS media and repeat as needed. 
9. Use protocol for passaging mammalian cells and plate the cells in the media created in step 8. 
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3. Image Characterization of Therapeutic Exosomes 
 
3.1 Design Description 
After creating our treatment stable cell line (HEK 293 CD63-TNFR-GFP), we wanted to ensure 
that the exosomes it produced had been successfully modified. To do this, we decided to track 
the exosomes at each stage of their biogenesis. As discussed in the introduction, exosomes 
originate from the intraluminal budding of multivesicular endosomes. Therefore, we decided to 
utilize RFP stains for both early and late stage endosomes to visualize if our modified exosomes 
followed this path of biogenesis. We also utilized a lysosome tracker, as late stage endosomes 
can be digested by lysosomes. Finally, we performed a co-transfection of our stable cell line with 
an exosome localizer and RFP to ensure that our TNFR-GFP construct had successfully localized 
onto the surface of exosomes. All of the stains and the co-transfection were performed in a 4-
chamber glass bottom plate, as shown in Figure 3.1.1. 
 
Figure 3.1.1: Schematic of characterizing stains in a four-chamber plate. 
 
3.2 Key Constraints 
The key constraints for this portion of the project centered on the transfection and staining 
efficiency of our reagents. Some factors affecting this are cell confluency, reagent age, and 
seeding uniformity. Cell confluency and seeding uniformity can also affect image quality.  
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3.3 Expected Results 
We expected to see the GFP on our modified exosomes colocalize with the both the early and 
late endosome stains, as well as the RFP exosome localizer. When overlaying images taken with 
RFP and GFP filters, we expected to see the two colors overlap and appear yellow. Final results 
are shown in section 6.2. 
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3.4 Materials and Methods 
The following tables (Table 3-1) includes the necessary materials to perform the characterization 
experiments outlined in section 3.1.  
Table 3-1: Materials for Characterization 
Material Company/Brand Model # 
Passaging Mammalian Cells 
Materials (See Appendix) 
  
CD63-TNFR-GFP stable cell line Created in lab N/A 
Early Endosomes-RFP, BacMam 
2.0 
ThermoFisher/CellLight C10587 
Late Endosomes-RFP, BacMam 2.0 
ThermoFisher/CellLight C10589 
LysoTracker Red DND-99 
ThermoFisher/Invitrogen L7528 
Opti-MEM Reduced Serum Media 
ThermoFisher Scientific 31985062 
4-chamber 35 mm glass-bottom 
plate 
In Vitro Scientific D35C4-20-1.5-N 
1 g/L polyethylenimine (PEI) 
transfection reagent 
Created in lab N/A 
CMV-XP-RFP-EF1α expression 
vector 
System Biosciences/XPack XPAK531PA-1 
35 mm glass-bottom plate 
Matsunami Glass D35-14-1.5-U 
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Methods 
Day 1 
1. Seed cells for endosome imaging 
1.1. Use protocol for passaging mammalian cells to seed HEK 293 CD63-TNFR-GFP 
cells into all chambers of the 4-chamber 35 mm glass bottom plate at a density of 2x105 
cells/ml with DMEM + FBS + PS media.  
1.1.1. Each chamber of the glass-bottom plate contains 500 µL; add cells one 
chamber at a time to ensure equal cell density.  
1.2. Designate the 4 chambers as early endosome, late endosome, lysosome, and no 
transfection.  
1.3. Incubate at 37°C for 24 hours. 
2. Seed cells for exosome imaging 
2.1. Use protocol for passaging mammalian cells to seed HEK 293 CD63-TNFR-GFP 
cells into five 35 mm glass bottom plates at a density of 2x105 cells/ml with DMEM + 
FBS + PS media.  
2.2. Designate 4 plates to be transfected with CMV-XP-RFP-EF1α DNA and one plate to 
remain untransfected for control.  
2.3. Incubate at 37°C for 24 hours. 
Day 2 
3. Transfect cells with late and early endosome markers 
3.1. Estimate the number of cells in each chamber via light microscopy.  
3.2. Add 2 µL of early or late endosome mix per 45,000 cells to respective chambers.  
3.3. Incubate at 37°C for 16-24 hours. 
4. Transfect cells with exosome marker (for each transfected dish) 
 4.1. Aliquot 100 µL of opti-MEM media.  
4.2. Since each dish requires about 2µg of CMV-XP-RFP-EF1α DNA and 5 µL of 1 g/L 
PEI is required to encapsulate 1 µg of DNA, add 10 µL of PEI to opti-MEM.  
 4.3. Allow PEI and opti-MEM mixture to sit at room temperature for 5 minutes.  
4.4. Add 2µg of CMV-XP-RFP-EF1α DNA to mixture and allow to sit at room 
temperature for 20 minutes.  
4.5. Add 100 µL of mixture to each transfected dish.  
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4.6. Incubate dishes at 37°C for 24 hours. 
Day 3 
5. Stain lysosomes and image all cells 
5.1. Dilute stock LysoTracker Red DND-99 to a concentration of 50-75nM in cell culture 
media. 
5.2 Add 1µL of lysosome stain to designated chamber.  
5.3 Incubate at 37°C for 45 minutes.  
6. Capture phase contrast, RFP, and GFP images of each transfection at 40x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 18 
4. Testing Efficacy of Therapeutic Exosomes: 
Direct Treatment 
 
4.1 Design Description 
After creating our stable cell line, we wanted to test the efficacy of our CD63-TNFR-GFP 
exosomes. To do this, we added TNFα to half of the wells of our HEK 293 Nfkb dual reporter 
cells to simulate inflammation as well as varying concentrations (0.5mg/ml, 0.1mg/ml, and 0 
mg/ml) of our CD63-TNFR-GFP treatment exosomes or our CD63-RFP-GFP control exosomes. 
Each experimental condition was run in triplicate. We then utilized a luciferase assay to 
determine whether our treatment exosomes had successfully inhibited TNFα initiated 
inflammation in vitro. 
 
4.2 Key Constraints 
The key constraints for this portion of the project centered on the response sensitivity and 
volume of the HEK 293 Nfkb dual reporter cells. These constraints were controlled by reporter 
system expression and the number of seeded cells, respectively. A second constraint was the 
degradation of the luciferase assay reagent (LAR). LAR is time and light sensitive, therefore our 
results also depended on this substrate’s quality.  
 
4.3 Expected Results 
We expected to see a statistically significant reduction in luciferase fluorescence--corresponding 
to a reduction in inflammation--only when we add CD63-TNFR-GFP exosomes. We also 
expected this response to be dependent on the exosome concentration. Final results are shown in 
section 6.3. 
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4.4 Materials and Methods 
The following table (Table 4-1) includes the materials required to perform the direct treatment 
efficacy assay.  
Table 4-1: Materials for Efficacy of Design Experiment: Direct Treatment 
Material Company/Brand Model # 
Passaging Mammalian Cells 
Materials (See Appendix) 
  
DMEM + 10% FBS + PS media Created in lab N/A 
 
Serum-Free Medium without L-
Glutamine   
BioWhittaker/ UltraCULTURE 12-725F 
 
96 well plate, clear bottom Greiner Bio-one/Cellstar 655180 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
Materials for Luciferase Assay (See 
Appendix A4) 
  
 
Methods 
Day 1 
1. Seed cells 
1.1 Use protocol for passaging mammalian cells to seed HEK 293 NfKB reporter cells 
into 36 wells of the 96-well plate at a density of 1x105 cells/ml with DMEM + FBS + PS 
media.  
1.2 Incubate the plate at 37°C for 24 hours.  
Day 2 
2. Treat cells with recombinant human TNFα and exosomes. 
2.1 Add recombinant human TNFα protein to serum-free media to create a stock 
concentration of 100 ng/mL TNFα. 
2.2. Create stock concentrations of CD63-TNFR-GFP exosomes of 0, 0.1, and 
0.5mg/mL in serum-free media. 
2.3. Create stock concentrations of CD63-RFP-GFP exosomes of 0, 0.1, and 
0.5mg/mL in serum-free media. 
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2.4. Add stock TNFα protein solution to appropriate exosome solutions to create a 
working concentration of 1 ng/mL TNFα.  
2.5 Tilt the plate and carefully aspirate the media off each well. 
2.6. Carefully add 100µL of the various serum-free media conditions to each well.  
2.7. Incubate at 37°C for 24 hours. 
Day 3 
3. Perform luciferase assay (See Appendix A4). 
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5. Testing Efficacy of Therapeutic Exosomes: Coculture 
 
5.1 Design Description 
In this experimental model, we wanted to determine the effect our CD63-TNFR-GFP exosomes 
would have in reducing inflammation in coculture with the HEK 293 Nfkb dual reporter cells. 
The cells were seeded in a 3:1 ratio of exosome producing cells to reporter cells. This allowed 
for a sufficient number of modified exosomes to be produced and released from the stable cell 
lines. HEK 293 CD63-RFP-GFP cells were used as control and plain HEK cells were used as 
background. Six wells of each coculture condition were plated and TNFα was added to half of 
the wells. A luciferase assay was then performed to determine the extent to which our exosomes 
inhibited TNFα. 
 
5.2 Key Constraints 
The biggest constraint with this experimental model was that we did not know how many 
exosomes were produced by the cells in coculture with the reporter cell line. Therefore, we were 
unable to determine an effective dosage of CD63-TNFR-GFP exosomes using this model.  
 
5.3 Expected Results 
We expected that the exosomes secreted by our stable cell line in coculture with the reporter cell 
line would effectively decrease levels of TNFα. However, since the overall concentration of 
treatment exosomes was likely lower in this model than in the direct treatment model, the effect 
was not as pronounced. Final results are shown in section 6.3. 
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5.4 Materials and Methods 
Table 5-1 includes the materials necessary to perform the coculture efficacy assay.  
 
Table 5-1 Materials for Efficacy of Design Experiment: Coculture 
Material Company/Brand Model # 
Passaging Mammalian Cells 
Materials (See Appendix) 
  
DMEM + 10% FBS + PS media Created in lab N/A 
 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
Serum-Free Medium without L-
Glutamine   
BioWhittaker/ UltraCULTURE 12-725F 
 
96 well plate, clear bottom 
Greiner Bio-one/Cellstar 655180 
Materials for Luciferase Assay (See 
Appendix A4) 
 N/A 
 
Methods 
Day 1 
1. Seed cells 
1.1 Create stock concentrations of exosome producing cells (HEK 293, HEK 293 CD63-
RFP-GFP, HEK 293 CD63-TNFR-GFP) and reporter cell line HEK 293-NfKB Dual 
Reporter in suspension at 1x105 cells/ml. 
1.2 Plate 100 ul per well comprised of 75 ul of exosome producing suspension and 25 ul 
of reporter cell suspension across the following groups: HEK 293 vs Reporter, RFP-GFP 
vs Reporter, TNFR-GFP vs Reporter.  
1.3 Incubate 48 hours 
Day 3 
2. Treat half the groups with Recombinant Human TNFα Protein at 1 ng/ml. Incubate 24 hours at 
37°C. 
Day 4 
3. Perform Luciferase Assay (See Appendix A4). 
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6. Results 
 
6.1 Creation of Stable Cell Lines 
We succeeded in creating a stable cell line that produces our modified, decoy exosomes, as well 
as a second stable cell line for experimental control. Figures 6.1.1 and 6.1.2 show the expression 
of our desired DNA constructs in HEK 293 cells. The localization of fluorescence to small dots 
outside the cells’ nuclei shows that our constructs have been integrated into the membranes of 
exosomes.  
 
Figure 6.1.1: HEK 293 CD63-TNFR-GFP stable cell line. Modified exosomes represented by GFP. 
 Images taken at 40x. 
 
Figure 6.1.2: HEK 293 CD63-RFP-GFP stable cell line for experimental control. Images taken at 40x. 
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6.2 Characterization 
Imaging confirmed that our desired modifications had been made to the surface of exosomes 
produced by the HEK 293 CD63-TNFR-GFP stable cell line. Images show colocalization of 
exosomes with both early and late stage endosomes (Figure 6.2.1 A and B), which demonstrates 
that our modifications are following the path of exosome biogenesis. As discussed in 1.2.3.1, 
exosomes may follow an alternate path and reside within lysosomes. Imaging shows that our 
modified exosomes also colocalize with lysosomes (Figure 6.2.1 C). An exosome-specific 
marker (XPACK-RFP) also colocalizes with our CD63-TNFR-GFP exosomes (Figure 6.2.2). 
Colocalization of each of the RFP markers with GFP is represented as yellow in the overlaid 
images.  
 
Figure 6.2.1: HEK 293 CD63-TNFR-GFP cells with A: Early Endosome RFP Marker, B: Late Endosome RFP 
Marker, and C: Lysosome RFP Marker. All images taken at 40x. 
 
Figure 6.2.2: HEK 293 CD63-TNFR-GFP cells with XPACK-RFP, an exosome localizer. Images taken at 40x. 
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6.3 Efficacy 
The presence of our treatment exosomes was successful in reducing levels of TNFα in both the 
coculture and direct treatment models. Inflammation was quantified in both models using the 
HEK 293 Nfkb dual reporter cell line. A decrease in levels of TNFα corresponds to a decrease in 
luminescence detected during our assay.  
 
As shown in Figure 6.3.1, our exosomes produced in coculture with the reporter cell line were 
able to significantly reduce (p=0.036) the levels of TNFα compared to the experimental 
condition with natural, HEK exosomes only.  
 
Figure 6.3.1: Efficacy of exosome producing stable cell lines in coculture with HEK 293 Nfkb dual reporter cells. 
N=9 from three separate trials. Error bars represent standard error of the mean. 
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The direct treatment model also showed a significant decrease in TNFα levels with the addition 
of 0.5mg/ml of CD63-TNFR-GFP exosomes (Figure 6.3.2).  
 
 
Figure 6.3.2: Efficacy of 0.5mg/ml exosomes added directly to HEK 293 Nfkb dual reporter cells. N=9 from three 
separate trials. Error bars represent standard error of the mean. 
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7. Discussion and Conclusion 
 
Our results show that the concept of an effective, exosomal decoy treatment for inflammation is 
possible. In the production phase of our project, we find that our stable cell lines expresses GFP 
and RFP, as expected. In the verification phase, we confirm that the particles our cell lines 
produce are exosomes due to colocalization features with other cell compartments. Most 
importantly, we prove that both models of efficacy experiments show a significant decrease in 
inflammation due to the presence of the exosomes we created. This fact, combined with the 
penetrative capacity known of exosomes and their longer biological half-life, indicates a solid 
footing into further exosome research for RA. If our treatment is proven to work in animal and 
human models, it has the potential to be one of the first exosomal treatments. Future work, such 
as purity testing, high-throughput production design, and observation of cytotoxic and organ 
system effects would be the best way to continue this project, but would require outside help and 
better equipment. 
 
We hope that our project will trigger more research into exosomal decoy therapies for other 
human diseases. Besides RA, exosomes have a promising ability to deliver enzymes to the lumen 
of the lysosomes for patients with a wide-variety of lysosomal storage diseases such as 
Gaucher’s or Tay Sachs.  
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8. Engineering Standards and Realistic Constraints 
 
8.1 Social impact 
By utilizing exosomes for our treatment, we believe that the therapeutic effects of our anchored 
TNF receptor will be superior to treatments utilizing soluble TNFR. This would primarily be due 
to exosomes’ long half-life in the body, as well as their ability to deeply penetrate inflamed 
tissues. This targeted therapeutic will also be less wasteful than current soluble TNFR 
treatments; soluble TNFR will degrade much faster than TNFR anchored to an exosomal 
membrane. Hopefully, this will result in the patient requiring fewer injections, which will 
improve their quality of life by decreasing the number of times they have to visit a doctor.  
 
8.2 Health and Safety 
Any medical therapy must undergo rigorous testing before being administered to humans. Our 
project is focused on manufacturing, characterizing, and testing therapeutic exosomes in vitro, 
and can therefore be classified as pre-clinical. The first step to ensuring the safety of our 
therapeutic would be to perform a toxicity assay in a mammalian cell culture model. 
Unfortunately, our lab does not have the resources to move forward with the next steps in safety 
testing. However, if our therapeutic were to proceed to clinical trials, it would be tested in 
animals before beginning four phases of human trials. 
 
8.3 Manufacturability 
A major issue encountered in our design project was the efficient and reliable production of 
engineered exosomes at a rate that would warrant its use as a therapeutic. Previous to our work 
on the project, the procurement of therapeutic exosomes required transient transfection of our 
construct immediately prior to each harvest being performed. Sustained gene expression 
guaranteed by stable cell lines allowed us to more quickly and reliably harvest therapeutic 
exosomes and cut down the cost incurred through prodigal use of transfection reagents.  
Further improvements to exosome harvest and purification could allow more efficient 
manufacturability in the future. Cellular exosome yield could be drastically heightened with the 
introduction of better, more suitable conditions using a controlled bioreactor. Modulation of pH, 
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temperature, or agitation may change the ability of our cells to produce exosomes. Additionally, 
the efficacy experiments indicated that a high concentration of exosomes induced a modest 
reduction in the inflammation pathway response. However, we have reason to believe that the 
concentration indicated by the nanodrop lite may erroneously register the additive effect of 
artifacts and thus display false readings. A better protein expression system to gauge the purity 
and true concentration of our purified exosomes is needed to achieve desired manufacturability. 
 
8.4 Economic 
As we noted in our introduction, novel biologics that work via inhibition of inflammatory 
cytokines IL-6 and TNFα have the potential to induce antagonistic antibody production or allow 
the reactivation of latent infections such as tuberculosis. These could lead to far more expensive 
medical costs. Furthermore, effective use of these therapies requires regular and expensive 
treatment. Our exosomes have the potential to reduce cost by limiting the number of times a 
patient must return for treatment. Exosomes boast a longer half-life in the body, and do not 
threaten to evoke deleterious immune responses that pile up the medical bills. 
 
8.5 Ethical implications 
We chose to work on this project because we believed that this novel treatment had the potential 
to impact the millions of people suffering from a disease as debilitating as rheumatoid arthritis. A 
chronic illness severely limits patients’ autonomy and can prevent them from living a satisfying 
life. We hope that a therapy that aids symptom management for RA will promote patients’ 
autonomy. From a utilitarian point of view, developing a new treatment that will be less 
expensive for patients, ease their pain, and require them to visit the doctor less often is doing 
moral good.  
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Appendix 
 
A1: Making Media: DMEM + 10% FBS + PS 
Table A1-1: Materials for Making Media 
Material Company/Brand Model # 
Dulbecco’s Modified Eagle 
Medium with L-Glutamine 
(DMEM) 
Thermo Fisher Scientific/Gibco 11965092  
Fetal Bovine Serum (FBS) Thermo Fisher Scientific/Gibco 10438034 
Penicillin-Streptomycin (PS) Thermo Fisher Scientific/Gibco 15140122 
 
 
1. Add 50 mL of FBS into a 500ml bottle of DMEM with L-Glutamine. 
2. Add 5 mL of PS to the combined FBS and DMEM. 
3. Mix thoroughly. 
4. Store at 4°C until needed. 
 
 
A2: Passaging Cells 
Table A2-1: Materials for Passaging Cells 
Material Company/Brand Model # 
DMEM + 10% FBS + PS media N/A N/A 
Phosphate Buffered Saline  
pH 7.4 (PBS) 
Thermo Fisher Scientific AM9625 
Trypsin 0.25% with phenol red Thermo Fisher Scientific  15050065 
15 mL conical-bottom centrifuge 
tubes 
VWR 89039-666 
 
 
1. Aspirate depleted media 
2. Wash with 3 mL of PBS. Pipet gently into side of plate. 
3. Aspirate PBS. 
4. Add 1.5 mL of trypsin to plate. 
5. Incubate at 37°C for 2 minutes. 
6. Deactivate trypsin with 4.5 mL of DMEM + 10% FBS + PS media.  
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7. Collect media in 15 mL centrifuge tube, spin at 1500 RPM for 5 minutes. 
8. Aspirate off supernatant. 
9. Resuspend the pellet in DMEM + 10% FBS + PS media. 
10. Plate at desired density. 
 
 
A3: Harvesting Exosomes 
Table A3-1: Materials for Exosome Harvest 
Material Company/Brand Model # 
Passaging Mammalian Cells 
Materials (See Appendix A1) 
  
Dish 145mmx20mm  Sigma-Aldrich/ Greiner 639160 
 
Serum-Free Medium without L-
Glutamine   
BioWhittaker/ UltraCULTURE 12-725F 
 
50 mL conical-bottom 
centrifuge tubes  
VWR  89039-658 
Syringe, 30 mL BD Biosciences/ BD Luer-Lok  
Sterile hydrophobic filter, 0.2 
micron  
BD Biosciences/ BD Influx  645270 
Exosome precipitation solution  SBI/ ExoQuick  EXOQ5A-1 
Phosphate-Buffered Saline pH 7.4 
(PBS)   
Thermo Fisher Scientific AM9625 
Cryogenic vials  Sigma-Aldrich/ Nalgene  V4757 
 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed stable cell lines 
onto 145mmx20mm dishes at 40-60% confluency (2-3x105 cells/mL) with DMEM + 
10% FBS + PS media. 
1.2. Incubate at 37°C for 24 hours or until 70-80% confluent. 
Day 2: 
2. Change media 
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2.1. Aspirate off DMEM + 10% FBS + PS media and replace with equal volume of 
serum-free media without L-glutamine. 
2.2. Incubate at 37°C for 48 hours.  
Day 4:  
4. Exosome Harvest Part I  
4.1. Collect the serum-free medium into a 50 mL centrifuge tube. 
4.2. Centrifuge the 50 mL centrifuge tube at 1500xg for 10 minutes. 
4.3. Filter the supernatant through a 0.2-micron filter with a sterile 30 mL syringe into a 
new 50 mL centrifuge tube. 
4.4. Add 1⁄4 of the supernatant volume of exosome precipitation solution.  
4.5. Incubate at 4°C for 24 hours. 
 
Day 5: 
5. Exosome Harvest Part II  
5.1. Centrifuge the 50 mL centrifuge tube from Day 4 at 3000xg for 45-90 minutes. 
5.2. Carefully aspirate off the supernatant, taking care to not disturb the pellet on the side 
of conical tube.  
5.3. Resuspend the pellet in 50 µl-100 µl of PBS. 
5.4. Store in a cryogenic vial at -80°C until needed. 
 
 
A4: Luciferase Assay 
Table A4-1: Materials for Luciferase Assay 
Material Company/Brand Model # 
Plate Reader BMG Lab Tech/LUMIstar Omega S/N 415-1717 
Luciferase Assay Buffer (LAB) Promega E1501 
Luciferase Assay Substrate (LAS) Promega E1501 
Passive Lysis Buffer (PLB) Promega E1501 
 
1. Prepare Luciferase Assay Reagent (LAR) by combining 10mL of LAB with an entire vial of 
LAS. Pipette up and down to mix. 
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2. Dilute the Passive Lysis Buffer (PLB) by combining stock with 4x volume of DI water. 
3. Add 20µL of diluted lysis buffer to each well. 
4. Mix with gentle rotations for 10 minutes. 
5. Turn on computer and plate reader. 
6. Set up plate reader to measure luminescence with a read time of 10 seconds and set the 
attenuation to none. 
7. Quickly add 100µL of LAR to each well, ensuring that the order in which you add the LAR is 
the order in which the plate reader will read the wells.  
8. Immediately run the plate in the plate reader. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
